Search Results | Blood | American Society of Hematology

1-20 of 91

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Management of AL amyloidosis in 2020

Giovanni Palladini, Paolo Milani, Giampaolo Merlini

Blood (2020) 136 (23): 2620–2627.

DOI: https://doi.org/10.1182/blood.2020006913

Published: 2020

Journal Articles

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Paolo Milani, MDPhD, Nelson Leung, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Ute Hegenbart, MD, Frank Bridoux, MD, Florent Joly, MD, Sascha A Tuchman, MD, Victor Jimenez-Zepeda, MD, Sriram Ravichandran, MBBS, MRCP, FRCPath, Holly Lee, MD, Tamara Berno, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-141662

Published: 2020

Journal Articles

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Giovanni Palladini, MD PhD, Paolo Milani, MDPhD, Simone Celant, Valentina Summa, MD, Giovanni Affronti, Pier Paolo Olimpieri, PhD, Sandra Petraglia, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Giampaolo Merlini, MD, Pierluigi Russo, MD PhD

Blood (2020) 136 (Supplement 1): 22.

DOI: https://doi.org/10.1182/blood-2020-141563

Published: 2020

Journal Articles

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Ashutosh D. Wechalekar, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD, Raymond L. Comenzo, MD, Arnaud Jaccard, MD PhD, NamPhuong Tran, MD, Huiling Pei, PhD, Sandra Y. Vasey, MSc, Brenda Tromp, MSc, Brendan M. Weiss, MD, Jessica Vermeulen, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 6–7.

DOI: https://doi.org/10.1182/blood-2020-140514

Published: 2020

Journal Articles

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Paolo Milani, MDPhD, Vaishali Sanchorawala, MD, Ramon Lecumberri, MD PhD, Sunil Saith, MD, Mathew S. Maurer, MD, M. Teresa Cibeira, MD PhD, Giampaolo Merlini, MD, Stefan Schönland, MD, Giovanni Palladini, MD PhD

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-141569

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

DOI: https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

DOI: https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

DOI: https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Clinical Trials & Observations

Blood (2020) 136 (1): 71–80.

DOI: https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Clinical Trials & Observations

Blood (2020) 135 (18): 1531–1540.

DOI: https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

Clinical Trials & Observations

Marco Basset, Irene Defrancesco, Paolo Milani, Mario Nuvolone, Sara Rattotti, Andrea Foli, Silvia Mangiacavalli, Marzia Varettoni, Pietro Benvenuti, Claudio Salvatore Cartia, Marco Paulli, Giampaolo Merlini, Luca Arcaini, Giovanni Palladini

Blood (2020) 135 (4): 293–296.

DOI: https://doi.org/10.1182/blood.2019002762

Published: 2020

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

DOI: https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

DOI: https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Paolo Milani, MD PhD, Francesca Fazio, MD, Marco Basset, MD, Tamara Berno, MD, Alessandra Larocca, Andrea Foli, MD, Marcello Riva, MD, Stefania Oliva, Jessica Ripepi, Mario Nuvolone, MD PhD, Maria Teresa Petrucci, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1860.

DOI: https://doi.org/10.1182/blood-2019-130675

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

DOI: https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

DOI: https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Clinical Trials & Observations

Masayoshi Tasaki, Paolo Milani, Andrea Foli, Laura Verga, Laura Obici, Marco Basset, Margherita Bozzola, Giovanni Ferraro, Mario Nuvolone, Patrizia Morbini, Gianluca Capello, Mitsuharu Ueda, Konen Obayashi, Marco Paulli, Yukio Ando, Giampaolo Merlini, Giovanni Palladini, Francesca Lavatelli

Blood (2019) 134 (3): 320–323.

DOI: https://doi.org/10.1182/blood.2019000420

Published: 2019

Journal Articles

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Paolo Milani, MD, Faye Sharpley, Stefan Schönland, Marco Basset, MD, Shameem Mahmood, Christoph Kimmich, Andrea Foli, MD, Sajitha Sachchithanantham, Giampaolo Merlini, MD, Ashutosh D. Wechalekar, Giovanni Palladini, MD PhD, Ute Hegenbart

Blood (2018) 132 (Supplement 1): 3264.

DOI: https://doi.org/10.1182/blood-2018-99-118034

Published: 2018

Journal Articles

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Paolo Milani, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 1985.

DOI: https://doi.org/10.1182/blood-2018-99-118108

Published: 2018

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

DOI: https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

2 3 4 5

NARROW

Management of AL amyloidosis in 2020

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis

Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only